Navigation Links
NuvOx Pharma Begins Clinical Trial to Treat Brain Cancer
Date:8/7/2014

Tucson, AZ (PRWEB) August 07, 2014

NuvOx Pharma, a privately held biotechnology company based in Tucson, Arizona, focused on developing a nanotechnology platform for reversing conditions with decreased oxygen announced that on July 14th, it began a Phase Ib clinical trial of its new drug NVX-108 in patients with glioblastoma, a deadly form of brain cancer.

Glioblastoma multiforme (GBM), according to the Central Brain Tumor Registry, affects about 10,300 patients per year in the US. Average survival is only about 12-months following standard therapy, which involves surgery followed by radiation and chemotherapy. GBM, like many other forms of cancer, is known to have low oxygen (hypoxia). Hypoxia adversely affects the response of tumors to radiation therapy and NVX-108 has been shown to raise tumor oxygen levels and improve the response to radiation therapy. The clinical trial is being performed at Monash University in Melbourne Australia. GBM patients who have residual tumor after surgery are receiving an IV dose of NVX-108 during each of the 30 fractions of radiation over a 6-week period. Up to about 25 patients will be treated in the trial. The primary end-point of the trial is safety, but the study will also determine the recommended dose for the drug and provide data on the 6-month survival of the patients. After completion of the trial NuvOx plans to file an investigational new drug application with the FDA and perform a Phase IIb trial in the US.

“We are very excited about moving NVX-108 into the first therapeutic trial. The parent compound, dodecafluoropentane, was previously studied as a contrast agent and was shown to be safe. Due to market considerations it was never launched as a contrast agent. We own that regulatory data and the FDA has agreed that we can reference it in support of clinical development to treat cancer,” said Evan Unger, MD, President and CEO of NuvOx.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12071710.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System
2. Sanuvox Releases the Aseptix Dual UV Sterilization System to Help Reduce Nosocomial (HAI) Infections in Hospital Environments
3. URAC Seeks Public Comments on Revised Specialty Pharmacy and Mail Service Pharmacy Accreditation Standards and Measures
4. Good Neighbor Pharmacy’s 2014 ThoughtSpot Inspires Independent Pharmacists to Transform Their Businesses
5. Harry Race Pharmacy Named 2014 Good Neighbor Pharmacy of the Year
6. Community pharmacist intervention boosts drug adherence, reduces health-care costs
7. Pharmaceuticals Wholesaling in Australia Industry Market Research Report Now Updated by IBISWorld
8. West Coast University Launches New Doctorate of Pharmacy Program
9. PharmaVOICE Honors Five PHCG Leaders Among 100 Healthcare Visionaries
10. US Pharmaceutical Packaging Products Worth $22.1 Billion by 2018 Says a New Research Report at LifeScienceIndustryResearch.com
11. Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: